HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU chemicals legislation

This article was originally published in The Rose Sheet

Executive Summary

European Commission's proposed Registration, Evaluation and Authorisation of Chemicals (REACH) system should account for economic impact on industry, including micro, small and medium-sized enterprises, participants stress at European Council conference on competitiveness Sept. 22. Released in May, draft reg requires registration of all chemicals placed on the market or imported into the EU (1"The Rose Sheet" Aug. 18, 2003, p. 8). A final version likely will be approved by the EC in late October. The policy would implement the White Paper on the Strategy for a Future Chemicals Policy, passed by the EU Parliament in 2001...

You may also be interested in...



EU Should Assess Risk Using Cosmetics Directive, Not Chemical Reg – CTFA

Risk assessment of raw materials used in cosmetics in the European Union should be addressed through the existing cosmetics directive rather than through a proposed chemical regulation, the Cosmetic, Toiletry and Fragrance Association states in comments to the European Commission

Quotable: Words Of Wisdom From Our Recent APAC Coverage

Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.

Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification

Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS011561

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel